Astellas Pharma

From SourceWatch
Jump to navigation Jump to search

In October 2009, Medivation announced a global agreement with Astellas Pharma Inc. to develop and commercialize enzalutamide (formerly MDV3100). [1]

Resources and articles

Related Sourcewatch

References

Retrieved from "https://www.sourcewatch.org/index.php?title=Astellas_Pharma&oldid=624238"